Tumor necrosis factor α blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of treg cells

Arthritis and Rheumatism

Volumn 62, Issue 2, 2010, Pages 430-440

  Ma, Hak Ling ^a   Napierata, Lee ^a   Stedman, Nancy ^a   Benoit, Stephen ^a   Collins, Mary ^a   Nickerson Nutter, Cheryl ^a   Young, Deborah A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45RB ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL EXPANSION; CELL LINEAGE; CONTROLLED STUDY; DISEASE EXACERBATION; GENE EXPRESSION; GENE REPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; LYMPH NODE; LYMPH NODE CELL; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; REGULATORY T LYMPHOCYTE; SKIN INFLAMMATION; TH17 CELL;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES; ANTIGEN-PRESENTING CELLS; CELLS, CULTURED; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-23; INTERLEUKIN-6; INTERLEUKINS; KERATINOCYTES; MICE; MICE, INBRED BALB C; MICE, SCID; PSORIASIS; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75749129902     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27203     Document Type: Article

References (46)

1. Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of the host response [review]. Annu Rev Immunol 1989;7:625-55.
2. Kehrl JH, Miller A, Fauci AS. Effect of tumor necrosis factor α on mitogen-activated human B cells. J Exp Med 1987;166:786-91.
3. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol 1988;141:2407-12.
4. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
5. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986;163:1433-50.
6. Turner M, Chantry D, Buchan G, Barrett K, Feldmann M. Regulation of expression of human IL-1α and IL-1β genes. J Immunol 1989;143:3556-61.
7. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3:745-56.
8. Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185:1573-84.
9. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
10. Chen X, Baumel M, Mannel DN, Howard OM, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 2007;179:154-61.
11. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al, for the Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
12. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
13. Yocum D. Effective use of TNF antagonists. Arthritis Res Ther 2004;6 Suppl 2:S24-30.
14. Braun J, Sieper J. Biological therapies in the spondyloarthritides - the current state. Rheumatology (Oxford) 2004;43:1072-84.
15. Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers [review]. Ann Rheum Dis 2005;64 Suppl 2:ii78-82.
16. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;15:996-1001.
17. Kary S, Worm M, Audring H, Huscher D, Renelt M, Sorensen H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists. Ann Rheum Dis 2006;65:405-7.
18. De Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31.
19. Roux CH, Brocq O, Leccia N, Giacchero D, Breuil V, Albert C, et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect? J Rheumatol 2007;34:434-7.
20. Borras-Blasco J, Gracia-Perez A, Nunez-Cornejo C, Rosique-Robles JD, Mateu-Puchades A, Castera MD, et al. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. J Clin Pharm Ther 2008;33:321-5.
21. Cassano N, Coviello C, Loconsole F, Miracapillo A, Vena GA. Psoriasis exacerbation after a flu-like syndrome during anti-TNF-α therapy. Eur J Dermatol 2006 16:316-7.
22. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008;118:597-607.
23. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-87.
24. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-51.
25. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:1037-44.
26. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92.
27. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007;56:1152-63.
28. Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO. IL-12, independently of IFN-γ, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 1999;162:7480-91.
29. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
30. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73.
31. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203:2271-9.
32. Dudda JC, Perdue N, Bachtanian E, Campbell DJ. Foxp3+ regulatory T cells maintain immune homeostasis in the skin. J Exp Med 2008;205:1559-65.
33. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3:253-7.
34. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-9.
35. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med 2005;202:135-43.
36. Gordon C, Wofsy D. Effects of recombinant murine tumor necrosis factor-α on immune function. J Immunol 1990;144:1753-8.
37. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 2007;448:484-7.
38. Fantini MC, Rizzo A, Fina D, Caruso R, Becker C, Neurath MF, et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 2007;37:3155-63.
39. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008;205:2491-7.
40. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor α and interferon γ by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003;62:561-4.
41. Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM. Inhibition of the TNF pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 2002;132:414-422
42. Jacob CO, McDevitt HO. Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis. Nature 1988;331:356-8.
43. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989;52:421-34.
44. Kim E, Chi H, Rajaiah R, Moudgil K. Exogenous tumour necrosis factor α induces suppression of autoimmune arthritis. Arthritis Res Ther 2008;10:R38.
45. Qin HY, Chaturvedi P, Singh B. In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-γ/TNF-α. Int Immunol 2004;16:1723-32.
46. Cope AP. Regulation of autoimmunity by proinflammatory cytokines [review]. Curr Opin Immunol 1998;10:669-76.